As of 20 Nov 2025, Lincoln Pharmaceuticals' stock price closed at ₹542.70, marking a day change of 2.09% from the previous close of ₹531.60. The stock's intraday range spanned from ₹529.05 to ₹542.70, positioning it closer to its 52-week low of ₹491.00 than its 52-week high of ₹975.00. This price behaviour underscores a period of consolidation following a significant correction over the past year.
Examining the technical trend, the stock has shifted from a bearish stance to a mildly bearish one. This subtle change suggests that while downward pressures remain, the intensity has somewhat moderated. The Moving Average Convergence Divergence (MACD) indicator presents a mixed picture: weekly readings lean mildly bullish, indicating some short-term positive momentum, whereas monthly readings remain mildly bearish, reflecting longer-term caution.
The Relative Strength Index (RSI), a momentum oscillator, currently shows no definitive signal on both weekly and monthly charts. This neutrality suggests that the stock is neither overbought nor oversold, implying a potential equilibrium in buying and selling pressures at present.
Bollinger Bands, which measure volatility and price levels relative to moving averages, indicate sideways movement on the weekly scale, signalling a consolidation phase. On the monthly scale, however, the bands suggest a mildly bearish outlook, hinting at possible downward pressure over a longer horizon.
Daily moving averages also reflect a mildly bearish trend, reinforcing the notion of subdued momentum in the near term. The Know Sure Thing (KST) indicator, which aggregates multiple rate-of-change calculations, remains bearish on both weekly and monthly timeframes, signalling persistent caution among market participants.
Dow Theory analysis adds further nuance: weekly signals are mildly bullish, suggesting some short-term optimism, while monthly signals remain mildly bearish, indicating that the broader trend has yet to fully recover. On-Balance Volume (OBV), a volume-based indicator used to confirm price trends, shows no clear trend on the weekly chart but is mildly bearish on the monthly chart, implying that volume flow may not be supporting a sustained upward move.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
From a returns perspective, Lincoln Pharmaceuticals has demonstrated a varied performance relative to the Sensex benchmark. Over the past week, the stock returned 3.14%, outpacing the Sensex's 0.85%. This trend continued over the last month, with the stock posting a 3.55% return compared to the Sensex's 1.47%. However, year-to-date figures reveal a contrasting scenario: Lincoln Pharmaceuticals recorded a negative return of -31.39%, while the Sensex gained 9.02% during the same period.
Looking at longer-term horizons, the stock's performance appears more favourable. Over one year, Lincoln Pharmaceuticals posted a -12.47% return against the Sensex's 9.81%. Yet, over three, five, and ten-year periods, the stock has outperformed the benchmark significantly, with returns of 78.02%, 135.44%, and 238.76% respectively, compared to the Sensex's 38.15%, 95.38%, and 229.64%. These figures highlight the stock's capacity for substantial growth over extended durations despite recent volatility.
Such mixed signals from technical indicators and return metrics suggest that Lincoln Pharmaceuticals is navigating a transitional phase. The mildly bearish longer-term technical outlook contrasts with pockets of short-term bullishness, indicating that investors should monitor evolving market conditions closely.
Why settle for Lincoln Pharmaceuticals ? SwitchER evaluates this Pharmaceuticals & Biotechnology micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Investors analysing Lincoln Pharmaceuticals should consider the broader sector context. The Pharmaceuticals & Biotechnology industry continues to face regulatory challenges, pricing pressures, and innovation demands, all of which can influence stock performance. The current technical parameters reflect these complexities, with no clear directional bias dominating the charts.
Moreover, the stock's proximity to its 52-week low suggests that market participants remain cautious, possibly awaiting clearer catalysts or fundamental developments. The absence of strong RSI signals further supports the view that the stock is in a consolidation phase, neither exhibiting strong buying enthusiasm nor significant selling pressure.
In summary, Lincoln Pharmaceuticals' recent technical momentum shift reveals a landscape of cautious optimism tempered by persistent bearish undertones. The interplay of mildly bullish weekly MACD and Dow Theory signals against monthly bearish trends and moving averages indicates a market in flux. Investors should weigh these factors alongside the stock's historical return profile and sector dynamics when considering their positions.
Given the current environment, a close watch on upcoming quarterly results, regulatory announcements, and sector developments will be essential to gauge whether Lincoln Pharmaceuticals can sustain any emerging positive momentum or if the prevailing caution will continue to dominate.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
